Do Yeun Kim
Overview
Explore the profile of Do Yeun Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
270
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yu S, Lee Y, Shin S, Woo G, Kim D, Kwon J, et al.
Support Care Cancer
. 2024 Nov;
32(12):796.
PMID: 39549104
Purpose: End-of-life decision-making, particularly relating to withholding life-sustaining treatment (LST), is a complex and emotionally charged process involving healthcare professionals, patients, and caregivers. Methods: This qualitative study explored the decision-making...
2.
Lee D, Lee S, Yoo S, Kim K, Kim M, Shin J, et al.
PLoS One
. 2024 May;
19(5):e0302011.
PMID: 38739589
Advancements in the treatment and management of patients with cancer have extended their survival period. To honor such patients' desire to live in their own homes, home-based supportive care programs...
3.
Ha H, Lee H, Kim J, Kim D, An H, Bae S, et al.
Cancer Res Treat
. 2024 May;
56(4):991-1013.
PMID: 38726510
Novel clinical trial designs are conducted in the precision medicine era. This study aimed to evaluate biomarker-driven, adaptive phase II trials in precision oncology, focusing on infrastructure, efficacy, and safety....
4.
Shin G, Kim B, Kim D, Bae S
BioDrugs
. 2024 Jan;
38(2):301-311.
PMID: 38212516
Introduction: Biosimilars offer a cost-effective alternative to original biopharmaceuticals with comparable efficacy and safety. The perception and familiarity of prescribers toward biosimilars play a critical role in their market penetration....
5.
Kim D, Lee H, Yu S, Kwon J, Ahn H, Kim J, et al.
J Hosp Palliat Care
. 2023 Sep;
24(4):204-213.
PMID: 37674642
Purpose: At the end of life, communication is a key factor for good care. However, in clinical practice, it is difficult to adequately discuss end-of-life care. In order to understand...
6.
Lee J, Kim M, Kim D, Shin H, Kang H, Koo B, et al.
Medicine (Baltimore)
. 2022 Oct;
101(38):e30301.
PMID: 36197176
Despite the urgent need to control dementia, an effective treatment has yet to be developed. Along with the Korean government's policy of cooperation between conventional medicine (CM) and Korean medicine...
7.
Ha H, Kang J, Kim D, Bae S, Lee H
BMC Health Serv Res
. 2022 Jul;
22(1):900.
PMID: 35821026
Purpose: Rapid development of novel therapeutics in renal cell carcinoma (RCC) has led to financial burden for patients and society. Value including clinical benefit, toxicity affecting quality of life and...
8.
Kim D, Ha H, Bae S, Kang J
J Korean Med Sci
. 2021 Jul;
36(29):e191.
PMID: 34313033
Background: As the role of immunotherapies and personalized medicine grow, cancer patients have faced many choices in treatments and have suffered financial toxicity. These challenges brought the need for the...
9.
Won Y, Kim H, Kwon J, Lee H, Baek S, Kim Y, et al.
Cancer Res Treat
. 2021 Jun;
53(4):908-916.
PMID: 34082495
Purpose: In Korea, the "Act on Hospice and Palliative Care and Decisions on Life-sustaining Treatment for Patients at the End of Life" was enacted on February 4, 2018. This study...
10.
Kim H, Kim Y, Kwon J, Won Y, Lee H, Baek S, et al.
Cancer Res Treat
. 2021 Jun;
53(4):917-925.
PMID: 34082494
Purpose: The main purpose of the Life-Sustaining Treatment Decisions Act recently enacted in Korea is to respect the patient's self-determination. We aimed to investigate the current status and features of...